Survival after combined modality therapy for pancreatic cancer

Howard W. Bruckner, Shalom Kalnicki, Jack Dalton, Harry Snady, Gary K. Schwartz, Margaret R. Chesser, Deborah Lehrer, John Mandeli, Noam Harpaz, Cynthia Janus

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Twenty consecutive patients with unresectable, locally advanced pancreatic cancer were treated with split courses of radiotherapy (RT) and simultaneous multidrug chemotherapy consisting of 5 fluorouracil, continuous infusion, streptozotocin, and cisplatin. A separate, retrospective study identified a group of 28 contemporary patients with less advanced pancreatic cancers, all of which were successfully resected. The survival rate of the two groups were similar over the first 2 years, although it initially favored the unresectable group. This pattern of survival among patients treated with combined modality therapy provides a basis for new studies. At the two clinical extremes, these include treatment of unrespectable tumors previously considered ineligible for this treatment and initial treatment before resection of stage I tumors.

Original languageEnglish (US)
Pages (from-to)199-203
Number of pages5
JournalJournal of clinical gastroenterology
Issue number3
StatePublished - Apr 1993
Externally publishedYes


  • 5-Fluorouracil
  • Chemotherapy
  • Cisplatin
  • Combined modality therapy
  • Pancreatic cancer
  • Radiotherapy
  • Streptozotocin

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Survival after combined modality therapy for pancreatic cancer'. Together they form a unique fingerprint.

Cite this